PET-based dosimetry aids in delivery of radiolabeled antibodies

04/22/2012 | MolecularImaging.net

Individualized PET/CT-based bone marrow dosimetry may be a more accurate tool than plasma-based dosimetry in the delivery of therapeutic radiolabeled antibodies in cancer patients, according to a study published in the Journal of Nuclear Medicine, in some cases allowing for higher doses of the therapeutic agent. The researchers used two 124I-labeled antibodies, cG250 and huA33.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN